Clinical Trials Logo
  1. Home
  2. Toxoplasmosis
  3. NCT03258762

Phase I Study of Pyrimethamine in Healthy Japanese and Caucasian Subjects

Toxoplasmosis Clinical Trial

Official title:
A Single Centre, Open-label, Parallel-group, Single Oral Dose Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Pyrimethamine in Healthy Japanese and Caucasian Male Subjects

Clinical Trial Summary

Pyrimethamine in combination with a sulphonamide is known to be effective in the treatment of toxoplasmosis. However, Pyrimethamine has not been approved by the Japanese regulatory body (Pharmaceutical and Medical Devices Agency [PMDA]/ Ministry of Health, Labor and Welfare [MHLW]). The pharmacokinetics (PK) of Pyrimethamine has been investigated following administration of Sulfadoxine/Pyrimethamine tablet in healthy Japanese subjects. However, the study did not provide sufficient information for approval of Pyrimethamine in Japan; hence, PMDA has requested confirmation of the PK of Pyrimethamine in another PK study in Japanese and Caucasian healthy subjects. This study will be a single centre, open-label, parallel-group, single oral dose study to evaluate the PK, safety and tolerability of Pyrimethamine in healthy Japanese and Caucasian male subjects. Subjects will undergo a screening visit within 30 days prior to first dose of the study drug. On Day 1, subjects will be administered a single oral dose of pyrimethamine 50 milligrams (mg) along with calcium folinate 15 mg after an overnight fast of at least 10 hours. Subjects will continue to receive calcium folinate once daily until Day 8 of the treatment period. Blood sampling for PK analysis and safety assessments will be performed prior to dosing and over 22 days after dosing. Each subject will participate in the study for approximately 2 months from screening to follow-up.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT03258762
Study type Interventional
Source GlaxoSmithKline
Contact
Status Completed
Phase Phase 1
Start date September 25, 2017
Completion date November 19, 2017
View Details
See also
  Status Clinical Trial Phase
Completed NCT01479361 - Antiretroviral Drug Interaction Study in Volunteers With HIV Phase 1
Not yet recruiting NCT05860998 - Measuring the Prevalence of Toxoplasmosis and Its Socio-economic Consequences
Not yet recruiting NCT05783778 - Evaluation of the Role of Latent Toxoplasmosis in Female Patients With Active Acne Vulgaris N/A
Not yet recruiting NCT04825600 - Diagnosis of Toxoplasma Gondii Infection by Exploration of Cellular Immunity (TOXCELL) N/A
Completed NCT03993093 - Prevalence of HIV +ve Cases With AIDS Defining Opportunistic Infections Among ART Naive Patients Attending ART Centre
Recruiting NCT00004317 - Pyrimethamine, Sulfadiazine, and Leucovorin in Treating Patients With Congenital Toxoplasmosis Phase 4
Withdrawn NCT03932656 - Latent Toxoplasmosis in Females With Borderline Personality Disorder
Not yet recruiting NCT05963295 - Toxoplasma Gondii Infection in Both Children and Adult Patients With Hematological Malignancies N/A
Not yet recruiting NCT06305468 - Prognosis of Disseminated and Cerebral Toxoplasmosis Hospitalized in Intensive Care in the Era of PCR Diagnosis
Completed NCT02011750 - Pilot Trial of Valproate as Adjunctive Treatment for Toxoplasma Gondii Infection in Early Course Schizophrenia Phase 4